VTGN - VistaGen Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

VistaGen Therapeutics, Inc.

343 Allerton Avenue
South San Francisco, CA 94080
United States
650-577-3600
http://www.vistagen.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees9

Key Executives

NameTitlePayExercisedYear Born
Mr. Shawn K. SinghCEO & Director576.67kN/A1963
Dr. H. Ralph SnodgrassFounder, Pres, Chief Scientific Officer & Director467.44kN/A1950
Mr. Jerrold D. Dotson CPACFO, VP & Sec.409.74kN/A1953
Mr. Mark Adrian McPartlandVP of Corp. Devel.319.62kN/A1966
Dr. Mark A. SmithChief Medical Officer467.44kN/A1955
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines to treat diseases and disorders of the central nervous system. It focuses on depressive and social anxiety disorders. The company's lead product candidate is AV-101 that is in Phase II clinical trial for the treatment of chronic neuropathic pain, epilepsy, major depressive disorder (MDD), parkinson's disease levodopa-induced dyskinesia, and others; PH94B, a neuroactive nasal spray that is in Phase II clinical trial for social anxiety disorder (SAD) and Phase III cross over study for SAD, and Phase IIa clinical trial for generalized anxiety disorder; and PH10, a neuroactive nasal spray that is in Phase IIa clinical trial for MDD. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with Pherin Pharmaceuticals, Inc.; BlueRock Therapeutics, LP; and Cato Research Ltd. The company was founded in 1998 and is headquartered in South San Francisco, California.

Corporate Governance

VistaGen Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.